title: Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).
authors.forename: D M
authors.initials: DM
authors.lastname: Simpson
authors.forename: J-M
authors.initials: JM
authors.lastname: Gracies
authors.forename: K
authors.initials: K
authors.lastname: Graham
authors.forename: M
authors.initials: M
authors.lastname: Hallett
authors.forename: J
authors.initials: J
authors.lastname: Miyasaki
authors.forename: M
authors.initials: M
authors.lastname: Naumann
authors.forename: B
authors.initials: B
authors.lastname: Russman
authors.forename: L
authors.initials: L
authors.lastname: Simpson
authors.forename: Y
authors.initials: Y
authors.lastname: So
mesh_terms: D001905:Botulinum Toxins / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018908:Muscle Weakness / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation / Q000503:physiopathology; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D012021:Reflex, Abnormal / Q000187:drug effects / Q000502:physiology; D015203:Reproducibility of Results
chemical_list: D009465:Neuromuscular Agents; D001905:Botulinum Toxins